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in severely obese diabetic patients having BS versus conventional/-
intensive antidiabetic therapy.1,2 Respectively, in these trials: patient 
numbers were 60 and 150, primary end points were 2-year HBA1C 
level ≤6.5% (with fasting glucose < 100 mg/dL and no anti-DM 
pharmacotherapy) and 1-year HBA1C levels ≤6%, and surgical 
interventions were gastric bypass and bilio-pancreatic diversion and 
gastric bypass and sleeve gastrectomy. As previously described,3 we 
calculated respective unadjusted RC (akin to relative risk), NNT, 
and 95% CI values.
Results: The patients in these trials did not suffer any serious compli-
cations from their BS. Respective RC, NNT, and corresponding (CI) 
values were 8.5 (2.0–36.4) and 1.33 (1.08–1.74) and 3.2 (1.2–8.4) 
and 3.68 (2.42–7.68).
Conclusion: In the short-term (1–2 years), BS was a highly effective 
means of eliminating DM in these patients. The perceived success rate 
depended on the precise criteria used to define diabetes and the type 
of BS, but due to small sample sizes apparent statistical significance 
cannot be discerned with confidence.
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Introduction: The problem of effective and rational treatment of no 
viral hepatitis is still actual. During several last years, the screening 
of the bioactivity of the list of semi-synthetic derivatives of alkaloid 
cytisine was held in our laboratories. The result was the synthesis 
of O,O dimethyl-N-cytinizylphosphate (cytisin amidophosphate). 
Hepatoprotective properties were noted on the several models of 
acute and chronic hepatitis. Purpose: to study the efficacy and safety 
of cytisin amidophosphate under the name of Cytaphat in patients 
with toxic hepatopathy.
Patients (or Materials) and Methods: A total of 142 patients (age, 
16–56) with the verified (by history, objective status, ultrasound, 
and according to biochemical tests) diagnosis of acute toxic hepatitis 
(poisoning with ethyl alcohol – 49; alcohol surrogates – 89; par-
acetamol – 3; reserpine – 1), who took treatment in the toxicologic 
department were included in the clinical research. The patients were 
randomly divided into 3 groups: 34 patients were taking Essentiale 
(200 mL of 5% glucose + 10 mL of Essentiale) IV once per day for 3 
days; 94 patients were taking Cytaphat (10 mg/kg + 200 mL of 5% 
glucose) IV once per day for 3 days; 14 patients were taking placebo 
(200 mL of 5% glucose) IV once per day for 3 days. The method of 
clinical trials was double-blind.
Results: Three days after the implementation of Essentiale or 
Cytaphat, all patients reported a significant (subjective opinion) 
recovery: reduction of the discomfort, epigastric pain and the pain 
in the right upper quadrant; normalizing of the appetite; patients 
become active and vigorous. Patients who received placebo, subjec-
tively felt slightly better, but a positive trend was almost absent. Eight 
of 14 patients had no positive changes during the first 3 days. The 
average period of elimination of toxic hepatopathy using Cytaphat 
is 2.8 days, Essentiale – 7.2 days, and placebo – 10.6 days. One 
patient withdrew from the research (female, 58 years old, without the 
 formation of cardiac anomaly) left because of the evolved tachycardia 
(120 beats/min) after the second infusion of the examined drug. The 
injection of the drug was discontinued. This led to the normalization 
of the patient’s state in 30 minutes. Cytaphat’s effect and Essentiale’s 
effect on biochemical parameters (AST, ALT, and bilirubin) is differ-
ent from effect of the placebo when employed to patients with acute 
toxic hepatitis. Antioxidant effect of Cytaphat is comparable with 
the effect of such as Essentiale.
Conclusion: The efficiency of the drug is considered to be very high; 
normalization of the state took less time compared with standard 
treatment, significant betterment is reached immediately after the 
first injection. Preliminary results give us a hope, that Cytaphat can 
become a first domestic cytoprotector with high efficiency.
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Introduction: The interplay between uptake and efflux transporters 
determines hepatic concentrations of drugs. Gd-BOPTA is a contrast 
agent used in liver magnetic resonance (MR) imaging that enters 
into human hepatocytes through OATP and exit unchanged into 
bile through MRP2. Rifampicin (RIF) is transported by the same 
membrane proteins and may compete with Gd-BOPTA for hepatic 
uptake. The aim of the study was then to elucidate the acute cel-
lular interactions between Gd-BOPTA and RIF in perfused rat liver 
preparations.
Patients (or Materials) and Methods: Normal and rats lacking the 
canalicular transporter Mrp2 were used to prepare the perfused rat 
livers. We perfused livers with 153Gd-DTPA and 153Gd-BOPTA and 
hepatic concentrations were measured using a gamma scintillation 
probe. After RIF perfusion, hepatic concentrations and bile excretion 
rates were measured using high-performance liquid chromatography.
Results: RIF perfusion greatly decreased bile flow. RIF vascular clear-
ance was maximal at time 50 minutes and decreased thereafter until time 
75 minutes. The hepatic concentrations steadily increased until the end 
of RIF perfusion. During the rinse period, an efflux of RIF from hepato-
cytes back to the systemic circulation was observed. RIF hepatic concen-
trations were higher in rats lacking Mrp2. When RIF was coperfused 
with Gd-BOPTA, the uptake index of Gd-BOPTA significantly decreased 
with increasing concentrations of perfused RIF. No effect of Gd-BOPTA 
perfused at 200 μ M was evidenced on 100 μ M RIF transport.
Conclusion: Drug–drug interactions through transporters deter-
mine the cellular concentrations of Gd-BOPTA and rifampicin. 
Furthermore, cellular concentrations regulate the Oatp-Mrp2 inter-
play by modulating transport through membranes.
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